The SunRISe-2 trial evaluating TAR-200 combined with cetrelimab vs chemoradiation in muscle-invasive bladder cancer has been ...

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) and keeping the price ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on CG Oncology, Inc. (CGON – Research Report). The ...

US-based pharmaceutical company Johnson & Johnson has discontinued its SunRISe-2 study for TAR-200 in muscle-invasive bladder cancer (MIBC) patients not undergoing radical cystectomy. The decision was ...

Analysis by Macmillan estimates that around 60,000 women diagnosed with cancer under the age of 50 are struggling with ...

Prostate cancer treatment can be lifesaving, but it can also cause many side effects. Learn how you can manage them.

The sun has set on Johnson & Johnson’s SunRISe-2 study. J&J called a halt to the phase 3 bladder cancer trial after an ...

Johnson & Johnson said on Monday it has discontinued a late-stage study testing its experimental drug to treat a type of ...

Johnson & Johnson (JNJ) has discontinued a Phase 2 study of its drug TAR-200 for the treatment of muscle-invasive bladder ...

Researchers are a step closer to revolutionizing how doctors use radiotherapy to treat patients with muscle-invasive bladder ...

A blood test, performed when metastatic prostate cancer is first diagnosed, can predict which patients are likely to respond to treatment and survive the longest. It can help providers decide which ...

Prostate cancer is a major health concern for men worldwide — often developing without any immediate warning signs. Catching ...